Clinical Trial Update: Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating the maximal usage pharmacokinetics and safety of ARQ-154 Foam 0.3% in pediatric participants with scalp and body psoriasis. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ARQ-154 Foam 0.3%

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Psoriasis | Phase 1 | Status: RECRUITING